Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
February 2017—Meridian Life Science released a new brochure on its best performing tropical and vector-borne antigens and antibodies, including its new Zika reagents. Important troubleshooting tips are included for reducing cross-reactivity in flavivirus assays and increasing IgM detection sensitivity.
February 2017—Centogene, a genetics company focused on the early diagnosis of rare hereditary disorders, has introduced the Illumina HiSeq X whole genome sequencing platform …
February 2017—WaveSense introduced its nRichDX system for the bulk isolation of target cells and nucleic acids from liquid biopsies. The nRichDX uses the company’s proprietary paramagnetic bead technology to enable the capture of circulating tumor cells and cell-free DNA or cell-free RNA in quantities sufficient for analysis by next-generation sequencing and PCR techniques.
February 2017—Applied Spectral Imaging has entered into a collaboration with ARUP Laboratories to facilitate the development and commercialization of advanced digital pathology solutions, enhancing workflow efficiencies and simplifying the management and accessibility of clinical data.
February 2017—PerkinElmer’s Opal Multicolor Immunohistochemistry products for use with Leica Biosystems’ fully automated Bond RX research staining platform is now available. The kits can visualize up to six biomarkers and a nuclear counterstain on a single tissue section with next-day results.
January 2017—Ortho Clinical Diagnostics announced that the Food and Drug Administration has cleared its Vitros Automation Solutions for use with Ortho’s Vitros chemistry, immunodiagnostics, and integrated systems.
January 2017—Qiagen launched its QIAscout, a novel instrument for isolation of viable single cells from samples to enable single-cell analysis for next-generation sequencing, polymerase chain reaction, and other downstream applications.
January 2017—Hardy Diagnostics announced its new product, C Diff Banana Broth, which is recommended as a selective detection broth for the recovery of Clostridium difficile from environmental samples. Its name is derived from the color change reaction when C. diff is present; the broth changes from a deep red, indicating a negative reaction, to a milky yellow, indicating a positive reaction.
January 2017—Thermo Fisher Scientific’s two Clariom brand of assays, Clariom D Pico and Clariom S Pico, are designed primarily for translational researchers to accelerate the discovery and validation of complex biomarker signatures derived from coding and noncoding RNA across the whole transcriptome. Based on industry-leading microarray technology, the Clariom Pico assay designs include up-to-date content curated from a large number of public sequence databases, including RefSeq, Noncode, Ensembl, VEGA, lncRNAWiki, and RNA Central, among others.
January 2017—iSpecimen and TriCore Reference Laboratories announced an agreement through which iSpecimen will serve as a TriCore channel partner for making patient biospecimens and associated data available for research. iSpecimen’s cloud-based technology will be used to tap into the flow of patients, specimens, and data running through the TriCore organization, matching researchers with a variety of annotated, de-identified samples.
